QualityStocks News - INVO Bioscience Achieves Major Milestone with Infertility Device, Expands Market Reach into Brazil

Share Article

Approval of infertility device launches INVO into broad Brazilian market

Today’s announcement paves the way for the more than 125 fertility centers in Brazil to begin offering infertile couples a safe and cost effective solution compared to traditional IVF

QualityStocks would like to highlight INVO Bioscience, a publicly traded medical device company focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development.

In the company’s news yesterday,

INVO Bioscience announced that the National Health Surveillance Agency (ANVISA) in Brazil has granted approval of the INVOcell for use as a Class II device, which will allow the sale of INVOcell in the Brazilian market.

The approval marks a significant milestone in INVO’s history, and opens the door for INVO to tap into one of the largest markets and fastest growing economies in the world.

“Approval in Brazil is a very important step in the success of INVOcell due to the strength of support in the country by medical thought leaders such as Dr. Coelho,” Kathleen Karloff, CEO of INVO stated in the press release. “Today’s announcement paves the way for the more than 125 fertility centers in Brazil to begin offering infertile couples a safe and cost effective solution compared to traditional IVF. We look forward to working with EcoMed, our distribution partner in Brazil, as they begin ramping up their sales and marketing efforts.”

The approval by ANVISA was triggered by the completion of a 40-patient clinical trial conducted in Rio de Janeiro, Brazil, to establish safety, efficacy and comparative in-vitro fertilization (IVF) measures of the INVOcell device.

The trial results, paired with clinical trial results from the Colombian Fertility and Sterility Center (CECOLFES) in Colombia, were submitted to ANVISA for the purpose of gaining registration and approval for the sale of the INVOcell device in Brazil.

INVOcell is CE Mark approved in Europe and Canada and is also available in many South American countries. Karloff noted that if INVOcell can capture 5 percent of the marketplace in Brazil, it could equate to more than $10 million in product sales.

The company also listed several advantages of the INVOcell device, including a reduced occurrence of multiple pregnancies and subsequent costs and complications; relative cost advantages of the INVOcell procedure as compared to traditional IVF treatments; and pregnancy rates comparable to traditional IVF treatments.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website